Amgen Inc. (NASDAQ:AMGN) received a $177.00 target price from analysts at Credit Suisse Group in a research report issued on Friday. The firm presently has a “hold” rating on the medical research company’s stock. Credit Suisse Group’s price objective would suggest a potential downside of 0.23% from the company’s current price.

Other analysts have also issued research reports about the company. Vetr lowered Amgen from a “strong-buy” rating to a “buy” rating and set a $178.82 price target for the company. in a report on Monday, April 3rd. Mizuho reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a report on Monday, April 3rd. Cowen and Company reiterated a “buy” rating and issued a $209.00 price target on shares of Amgen in a report on Thursday, April 27th. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the company a “buy” rating in a report on Tuesday, May 9th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $198.00 price target (down previously from $200.00) on shares of Amgen in a report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have assigned a buy rating and three have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $185.17.

Shares of Amgen (NASDAQ:AMGN) traded up 0.15% on Friday, hitting $177.40. The stock had a trading volume of 2,692,421 shares. The company has a 50-day moving average of $162.22 and a 200-day moving average of $162.64. Amgen has a 52-week low of $133.64 and a 52-week high of $184.21. The company has a market cap of $130.46 billion, a P/E ratio of 16.85 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.00 by $0.15. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the previous year, the business earned $2.90 earnings per share. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, equities analysts anticipate that Amgen will post $12.47 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Amgen Inc. (AMGN) Given a $177.00 Price Target at Credit Suisse Group” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/07/17/amgens-amgn-hold-rating-reaffirmed-at-credit-suisse-group.html.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in the stock. Lyell Wealth Management LP acquired a new stake in Amgen during the fourth quarter valued at approximately $1,817,000. Greenwood Capital Associates LLC raised its stake in Amgen by 3.9% in the fourth quarter. Greenwood Capital Associates LLC now owns 13,981 shares of the medical research company’s stock valued at $2,044,000 after buying an additional 527 shares during the last quarter. Ally Financial Inc. acquired a new stake in Amgen during the fourth quarter valued at approximately $2,632,000. Nations Financial Group Inc. IA ADV acquired a new stake in Amgen during the fourth quarter valued at approximately $252,000. Finally, Marietta Wealth Management LLC acquired a new stake in Amgen during the fourth quarter valued at approximately $1,379,000. 78.80% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.